Cheryl L Cox1, M Robyn Andersen2, Aimee K Santucci1, Les L Robison1, Melissa M Hudson3. 1. St. Jude Children's Research Hospital. 2. The division of Public Health Sciences, The Fred Hutchinson Cancer Research Center. 3. Department of Hematology/Oncology, St. Jude Children's Research Hospital.
Abstract
PURPOSE/ OBJECTIVES: To document the per survivor and per additional survivor screening costs of a mailed survivorship care plan (SCP) with advanced practice nurse (APN) telephone counseling (SCP+C) or without APN telephone counseling (SCP). . DESIGN: Randomized, longitudinal clinical trial. . SETTING: St. Jude Children's Research Hospital in Memphis, Tennessee. . SAMPLE: 411 at-risk pediatric cancer survivors (aged 26-59 years), stratified by age (younger than 30 years versus 30 years or older), recommended screening frequency (every one, two, or five years), gender, and cancer diagnosis (hematologic versus solid tumor). . METHODS: Clinical and resource data costs were derived from trial data and external estimates. . MAIN RESEARCH VARIABLES: The cost-effectiveness of left ventricular systolic function screening per survivor and per each additional survivor screened. . FINDINGS: The per-survivor costs of SCP (n = 206) and SCP+C (n = 205) were $74.91 and $224.69, respectively. The estimated costs of SCP and SCP+C per additional survivor screened for two years disseminated in a medium-sized clinic (n = 101 survivors annually) were $345.41 and $293.85, respectively. . CONCLUSIONS: Adding APN counseling to a printed SCP may help preserve cardiac health at little or no cost per additional survivor screened. . IMPLICATIONS FOR NURSING: APN counseling is cost-effective and superior to the standard of care in supporting at-risk survivors' cardiac screening participation.
PURPOSE/ OBJECTIVES: To document the per survivor and per additional survivor screening costs of a mailed survivorship care plan (SCP) with advanced practice nurse (APN) telephone counseling (SCP+C) or without APN telephone counseling (SCP). . DESIGN: Randomized, longitudinal clinical trial. . SETTING: St. Jude Children's Research Hospital in Memphis, Tennessee. . SAMPLE: 411 at-risk pediatric cancer survivors (aged 26-59 years), stratified by age (younger than 30 years versus 30 years or older), recommended screening frequency (every one, two, or five years), gender, and cancer diagnosis (hematologic versus solid tumor). . METHODS: Clinical and resource data costs were derived from trial data and external estimates. . MAIN RESEARCH VARIABLES: The cost-effectiveness of left ventricular systolic function screening per survivor and per each additional survivor screened. . FINDINGS: The per-survivor costs of SCP (n = 206) and SCP+C (n = 205) were $74.91 and $224.69, respectively. The estimated costs of SCP and SCP+C per additional survivor screened for two years disseminated in a medium-sized clinic (n = 101 survivors annually) were $345.41 and $293.85, respectively. . CONCLUSIONS: Adding APN counseling to a printed SCP may help preserve cardiac health at little or no cost per additional survivor screened. . IMPLICATIONS FOR NURSING: APN counseling is cost-effective and superior to the standard of care in supporting at-risk survivors' cardiac screening participation.
Authors: Melissa M Hudson; Wendy Leisenring; Kayla K Stratton; Nina Tinner; Brenda D Steen; Susan Ogg; Linda Barnes; Kevin C Oeffinger; Leslie L Robison; Cheryl L Cox Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2009-04-14 Impact factor: 24.094
Authors: Steven E Lipshultz; M Jacob Adams; Steven D Colan; Louis S Constine; Eugene H Herman; Daphne T Hsu; Melissa M Hudson; Leontien C Kremer; David C Landy; Tracie L Miller; Kevin C Oeffinger; David N Rosenthal; Craig A Sable; Stephen E Sallan; Gautam K Singh; Julia Steinberger; Thomas R Cochran; James D Wilkinson Journal: Circulation Date: 2013-09-30 Impact factor: 29.690
Authors: Kevin C Oeffinger; Melissa M Hudson; Ann C Mertens; Stephanie M Smith; Pauline A Mitby; Debra A Eshelman-Kent; Jennifer S Ford; Judith K Jones; Sharmila Kamani; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2010-12-16 Impact factor: 3.167
Authors: Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer Journal: Lancet Oncol Date: 2015-03 Impact factor: 41.316
Authors: F Lennie Wong; Smita Bhatia; Wendy Landier; Liton Francisco; Wendy Leisenring; Melissa M Hudson; Gregory T Armstrong; Ann Mertens; Marilyn Stovall; Leslie L Robison; Gary H Lyman; Steven E Lipshultz; Saro H Armenian Journal: Ann Intern Med Date: 2014-05-20 Impact factor: 25.391
Authors: Elvira C van Dalen; Helena J H van der Pal; Wouter E M Kok; Huib N Caron; Leontien C M Kremer Journal: Eur J Cancer Date: 2006-09-20 Impact factor: 9.162
Authors: Rebecca E Hill; Claire E Wakefield; Richard J Cohn; Joanna E Fardell; Mary-Ellen E Brierley; Emily Kothe; Paul B Jacobsen; Kate Hetherington; Rebecca Mercieca-Bebber Journal: Oncologist Date: 2019-10-25
Authors: Rebecca E Hill; Claire E Wakefield; Richard J Cohn; Joanna E Fardell; Mary-Ellen E Brierley; Emily Kothe; Paul B Jacobsen; Kate Hetherington; Rebecca Mercieca-Bebber Journal: Oncologist Date: 2019-10-25